AllianceBernstein’s Amylyx Pharmaceuticals AMLX Stock Holding History

AllianceBernstein’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.45M	Buy	104,400 +23,600	+29%	+$365K	﹤0.01%	2203
2026 Q1	$976K	Buy	80,800 +9,300	+13%	+$131K	﹤0.01%	2348
2025 Q4	$864K	Hold	71,500	–	–	﹤0.01%	2408
2025 Q3	$972K	Buy	71,500 +40,900	+134%	+$385K	﹤0.01%	2362
2025 Q2	$196K	Buy	+30,600	New	+$149K	﹤0.01%	3058
2024 Q2	–	Sell	-51,542	Closed	-$146K	–	3235
2024 Q1	$146K	Hold	51,542	–	–	﹤0.01%	2984
2023 Q4	$759K	Hold	51,542	–	–	﹤0.01%	2405
2023 Q3	$944K	Hold	51,542	–	–	﹤0.01%	2279
2023 Q2	$1.11M	Hold	51,542	–	–	﹤0.01%	2222
2023 Q1	$1.51M	Buy	51,542 +15,300	+42%	+$532K	﹤0.01%	2019
2022 Q4	$1.34M	Hold	36,242	–	–	﹤0.01%	2136
2022 Q3	$1.02M	Buy	36,242 +342	+1%	+$8.53K	﹤0.01%	2278
2022 Q2	$691K	Buy	+35,900	New	+$426K	﹤0.01%	2529

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

AllianceBernstein's AMLX Position: Q2 2026 in Review

AllianceBernstein increased its Amylyx Pharmaceuticals (AMLX) stake by 29% in Q2 2026, buying an estimated $365K and bringing the position to 104,400 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2203.

AllianceBernstein first reported a position in AMLX in Q2 2022 and has held it in 13 quarters since. The position peaked at $1.51M in Q1 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

AllianceBernstein held 104,400 shares of Amylyx Pharmaceuticals worth $1.45M as of Q2 2026.
AllianceBernstein bought 23,600 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $365K.
Amylyx Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2203 holding.
AllianceBernstein first reported a position in Amylyx Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
AllianceBernstein's Amylyx Pharmaceuticals position peaked at $1.51M in Q1 2023.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.